StockDuty ← Dashboard Nov 13, 2026 05:25 PM ET
SignalEarnings

CRMD Stock Down 9% Despite Q3 Earnings and Revenues Beat Estimates

Q3 earnings and revenues beat estimates, yet CRMD stock fell 9%.

What happened: CorMedix Therapeutics $CRMD reported third-quarter 2026 results that beat estimates on adjusted loss per share and revenue, but the stock fell 8.7% after the release. Key numbers: Adjusted loss 4 cents per share vs. Why it matters: The decline reflected concerns over lower realized prices for DefenCath after its transition to post-TDAPA net pricing on July 1, 2026. Management deferred 2027 DefenCath revenue guidance to early 2027, citing uncertainty over quarterly Medicare reimbursement changes. Market: -2.5% today ($28.73), +622.3% YTD, 0.3x vol — as of 17:17 UTC Coverage: 5 outlets in 24h
CorMedix Therapeutics $CRMD reported third-quarter 2026 results that beat estimates on adjusted loss per share and revenue, but the stock fell 8.7% after the release.
The decline reflected concerns over lower realized prices for DefenCath after its transition to post-TDAPA net pricing on July 1, 2026. Management deferred 2027 DefenCath revenue guidance to early 2027, citing uncertainty over quarterly Medicare reimbursement changes. Market: -2.5% today ($28.73), +622.3% YTD, 0.3x vol — as of 17:17 UTC
Sources